Literature DB >> 19275767

RAGE: a novel biological and genetic marker for vascular disease.

Anastasia Z Kalea1, Ann Marie Schmidt, Barry I Hudson.   

Abstract

RAGE [receptor for AGEs (advanced glycation end-products)] plays an important role in the development and progression of vascular disease. Studies in cultured cells and small animal models of disease have clearly demonstrated that RAGE is central to the pathogenesis of vascular disease of the macro- and micro-vessels in both the diabetic and non-diabetic state. Emerging results from human clinical studies have revealed that levels of circulating soluble RAGE in the plasma may reflect the presence and/or extent of vascular disease state. Additionally, genetic variants of the RAGE gene (AGER in HUGO nomenclature) have been associated with vascular disease risk. Combining RAGE circulating protein levels and the presence of particular RAGE polymorphisms may be a useful clinical tool for the prediction of individuals at risk for vascular disease. Therapeutic intervention targeted at the RAGE gene may therefore be a useful means of treating pathologies of the vasculature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19275767     DOI: 10.1042/CS20080494

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  70 in total

1.  Early release of soluble receptor for advanced glycation endproducts after severe trauma in humans.

Authors:  Mitchell J Cohen; Michel Carles; Karim Brohi; Carolyn S Calfee; Pamela Rahn; Mariah S Call; Brian B Chesebro; Michael A West; Jean-François Pittet
Journal:  J Trauma       Date:  2010-06

Review 2.  The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Circ Res       Date:  2010-03-19       Impact factor: 17.367

3.  Rutin Inhibits Neuroinflammation and Provides Neuroprotection in an Experimental Rat Model of Subarachnoid Hemorrhage, Possibly Through Suppressing the RAGE-NF-κB Inflammatory Signaling Pathway.

Authors:  Guangzhi Hao; Yushu Dong; Rentao Huo; Kai Wen; Yinsong Zhang; Guobiao Liang
Journal:  Neurochem Res       Date:  2016-02-11       Impact factor: 3.996

4.  Plantar fascia thickness is longitudinally associated with retinopathy and renal dysfunction: a prospective study from adolescence to adulthood.

Authors:  Paul Z Benitez-Aguirre; Maria E Craig; Alicia J Jenkins; Patricia H Gallego; Janine Cusumano; Anthony C Duffin; Stephen Hing; Kim C Donaghue
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

5.  AGE-RAGE Stress in the Pathophysiology of Atrial Fibrillation and Its Treatment.

Authors:  Kailash Prasad
Journal:  Int J Angiol       Date:  2019-12-09

6.  Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS).

Authors:  Barry I Hudson; Yeseon Park Moon; Anastasia Z Kalea; Minesh Khatri; Chensy Marquez; Ann Marie Schmidt; Myunghee C Paik; Mitsuhiro Yoshita; Ralph L Sacco; Charles DeCarli; Clinton B Wright; Mitchell S V Elkind
Journal:  Atherosclerosis       Date:  2011-01-21       Impact factor: 5.162

7.  A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women.

Authors:  Liang Chen; Zhigang Duan; Lesley Tinker; Haleh Sangi-Haghpeykar; Howard Strickler; Gloria Y F Ho; Marc J Gunter; Thomas Rohan; Craig Logsdon; Donna L White; Kathryn Royse; Hashem B El-Serag; Li Jiao
Journal:  Cancer Epidemiol       Date:  2016-04-18       Impact factor: 2.984

8.  In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system.

Authors:  Ali Hafez Ali Mohammed El-Far; Seiichi Munesue; Ai Harashima; Akira Sato; Mika Shindo; Shingo Nakajima; Mana Inada; Mariko Tanaka; Akihiko Takeuchi; Hiroyuki Tsuchiya; Hiroshi Yamamoto; Hazem M E Shaheen; Yasser S El-Sayed; Shuhei Kawano; Sei-Ichi Tanuma; Yasuhiko Yamamoto
Journal:  Oncol Lett       Date:  2018-01-29       Impact factor: 2.967

9.  Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.

Authors:  Y Yu; K F Hanssen; V Kalyanaraman; A Chirindel; A J Jenkins; A J Nankervis; P A Torjesen; H Scholz; T Henriksen; B Lorentzen; S K Garg; M K Menard; S M Hammad; J A Scardo; J R Stanley; M Wu; A Basu; C E Aston; T J Lyons
Journal:  BJOG       Date:  2012-08-20       Impact factor: 6.531

10.  Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.

Authors:  Johanna W M Nin; Anders Jorsal; Isabel Ferreira; Casper G Schalkwijk; Martin H Prins; Hans-Henrik Parving; Lise Tarnow; Peter Rossing; Coen D A Stehouwer
Journal:  Diabetes       Date:  2010-06-03       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.